BCWORLD PHARM. Co. Ltd
BCWORLD PHARM. Co., Ltd. operates as a pharmaceutical company in South Korea. The company provides products in various therapeutic areas comprising musculoskeletal system, digestive system, circulatory machine, central nervous system, adrenocorticosteroids, narcotic analgesics, erectile dysfunction treatment, wellbeing injection, diuretic, antitussive expectorant, vaginitis treatment, anti-tuberc… Read more
BCWORLD PHARM. Co. Ltd (200780) - Total Liabilities
Latest total liabilities as of September 2025: ₩101.30 Billion KRW
Based on the latest financial reports, BCWORLD PHARM. Co. Ltd (200780) has total liabilities worth ₩101.30 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BCWORLD PHARM. Co. Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how BCWORLD PHARM. Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BCWORLD PHARM. Co. Ltd Competitors by Total Liabilities
The table below lists competitors of BCWORLD PHARM. Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NatureWise Biotech & Medicals Corporation
TWO:4732
|
Taiwan | NT$68.06 Million |
|
Alfabs Australia Ltd
AU:AAL
|
Australia | AU$66.95 Million |
|
Alpha Exploration Ltd
V:ALEX
|
Canada | CA$395.82K |
|
Soosung Innovation Co. Ltd.
KQ:084180
|
Korea | ₩137.40 Billion |
|
Kleannara
KO:004540
|
Korea | ₩448.75 Billion |
|
Greenland Hong Kong Holdings Limited
F:QFRA
|
Germany | €92.70 Billion |
|
MFO SA
WAR:MFO
|
Poland | zł290.43 Million |
|
Forian Inc
NASDAQ:FORA
|
USA | $10.17 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down BCWORLD PHARM. Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BCWORLD PHARM. Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BCWORLD PHARM. Co. Ltd (2015–2024)
The table below shows the annual total liabilities of BCWORLD PHARM. Co. Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩99.65 Billion | -2.75% |
| 2023-12-31 | ₩102.47 Billion | -1.00% |
| 2022-12-31 | ₩103.50 Billion | +5.72% |
| 2021-12-31 | ₩97.90 Billion | +7.27% |
| 2020-12-31 | ₩91.27 Billion | +20.83% |
| 2019-12-31 | ₩75.53 Billion | +5.42% |
| 2018-12-31 | ₩71.65 Billion | +93.06% |
| 2017-12-31 | ₩37.11 Billion | +64.62% |
| 2016-12-31 | ₩22.54 Billion | +88.58% |
| 2015-12-31 | ₩11.96 Billion | -- |